CD47 and acute myeloid leukemia: Magrolimab, an anti-CD47 monoclonal antibody, is a promising targeted agent for pediatric acute myeloid leukemia (pAML), a patient population with a high need for novel therapeutics to improve current poor clinical outcomes.